United Asset Strategies Inc. Purchases 1,048 Shares of Edwards Lifesciences Corporation $EW

United Asset Strategies Inc. grew its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 0.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 186,619 shares of the medical research company’s stock after purchasing an additional 1,048 shares during the quarter. Edwards Lifesciences makes up 1.2% of United Asset Strategies Inc.’s holdings, making the stock its 21st biggest holding. United Asset Strategies Inc.’s holdings in Edwards Lifesciences were worth $14,595,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. Quantbot Technologies LP bought a new stake in shares of Edwards Lifesciences during the 1st quarter valued at about $26,000. SouthState Corp bought a new stake in Edwards Lifesciences during the 1st quarter worth approximately $27,000. Rosenberg Matthew Hamilton purchased a new stake in shares of Edwards Lifesciences in the second quarter worth approximately $28,000. Costello Asset Management INC bought a new position in shares of Edwards Lifesciences in the first quarter valued at approximately $29,000. Finally, NewSquare Capital LLC boosted its position in shares of Edwards Lifesciences by 57.8% during the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after buying an additional 134 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 1,020 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,816,265.10. The trade was a 4.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the sale, the chief financial officer owned 39,898 shares in the company, valued at approximately $3,314,725.84. The trade was a 24.58% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 22,970 shares of company stock worth $1,862,878 over the last three months. Company insiders own 0.34% of the company’s stock.

Edwards Lifesciences Trading Up 1.3%

EW stock opened at $85.14 on Wednesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The company has a market capitalization of $49.41 billion, a PE ratio of 12.25, a price-to-earnings-growth ratio of 3.97 and a beta of 1.03. The company’s 50 day moving average price is $77.90 and its two-hundred day moving average price is $77.53. Edwards Lifesciences Corporation has a one year low of $64.89 and a one year high of $87.09.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter last year, the business earned $0.67 earnings per share. The business’s revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently weighed in on EW shares. BTIG Research upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a report on Tuesday, July 29th. Sanford C. Bernstein restated a “market perform” rating and set a $90.00 price target on shares of Edwards Lifesciences in a research report on Monday, November 3rd. Truist Financial raised their price objective on shares of Edwards Lifesciences from $87.00 to $90.00 and gave the stock a “hold” rating in a report on Monday, November 3rd. Daiwa America raised shares of Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 29th. Finally, UBS Group reissued a “neutral” rating and set a $90.00 price objective on shares of Edwards Lifesciences in a report on Monday, November 3rd. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $91.39.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.